Stock Ratings / Health Care / SGP / financials

IRMD (68) AORT (54) PRCT (48) SIBN (48) ⌘ Pro Terminal →

SpyGlass Pharma Inc. (SGP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$32.51 -1.06% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $32.39

SpyGlass Pharma Inc. (SGP) carries a Roarable Rating of D- (Sell) with 41/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.09B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $32.39 (-0.38%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (41/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SGP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (41/100 Composite)

🔍 WHY SGP SCORES 41/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (29% of score)

FRED Regime × Technicals: 92% of 52W Range • RSI-14 at 71.4 (OVERBOUGHT (>70))

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$24.92-3.7% Next Q

Q2 (-2Q)

Grade E$24.00+18.7% Next Q

Q3 (-1Q)

Grade E$28.48+14.2% Next Q

Current

Grade D-$32.51-7.2% Hist 90D α

Trajectory: E (33) → D- (41)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SGP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SGP currently carries a cautious 41/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($27.23) and Max Pain ($34.14) forces dealer call-delta covering toward $35.53.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SGP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SGP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 41%NO 59%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SGP Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-1%	-$39.9M	-$33.5M	-45%
FY 2024	$4.00B	52%	-0.7%	-$29.2M	-$24.0M	-45%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SGP)

✓Walkthrough of SGP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SGP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +41.72%📐 HORIZONTAL RANGE

2026-10-30O $32.21H $32.93L $31.75C $32.51VOL 94.1K

RES: $36.66SUP: $21.82SMA50: $27.23SMA200: $24.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SGP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SGP Butterfly Map → + Track SGP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SGP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SGP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SGP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SGP)

Health Care Rank #606 of 1016 ⚔️ IRMD vs SGP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SGP vs. IRMD, AORT, PRCT, SIBN)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, SpyGlass Pharma Inc. (SGP) ranks #606 by composite RQD confidence (41/100, grade D-) and #354 by equity capitalization ($1.09B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with SGP at 41/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SGP ACTIVE SpyGlass Pharma Inc.	D-	41/100	—	—	-35.0%	-1.06%	$1.09B	Benchmark Subject
IRMD iRadimed Corporation	C+	68/100	48.8x	76.7%	37.7%	+2.16%	$1.10B	/irmd-vs-sgp →
AORT Artivion Inc.	D+	54/100	117.0x	64.4%	4.5%	+2.27%	$1.14B	/aort-vs-sgp →
PRCT PROCEPT BioRobotics Corporation	D	48/100	—	63.7%	-35.0%	+0.50%	$1.16B	/prct-vs-sgp →
SIBN SI-BONE Inc.	D	48/100	—	79.6%	-10.3%	+2.66%	$1.00B	/sibn-vs-sgp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001778922

In its most recent audited fiscal period (FY2025, filed 2025-12-31), SpyGlass Pharma Inc. (SGP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$39.9M, operating cash flow of -$32.7M, and free cash flow of -$33.5M (-39.4% YoY). On the balance sheet, SGP closed FY2025 with $115.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$39.9M	-$32.7M	-$33.5M	$115.9M	—
FY2024 (FY)	2024-12-31	$0	-$29.2M	-$22.0M	-$24.0M	$23.3M	—

3. SGP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SGP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, SpyGlass Pharma Inc. (NASDAQ: SGP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 41/100 at a spot price of $32.51 (-1.06% 1D, market cap $1.09B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SGP ranks #606 in composite RQD confidence.

How does SGP compare to IRMD and AORT in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SGP carries a Roarable D- (41/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRMD (iRadimed Corporation) holds a C+ grade (68/100 RQD, P/E 48.8x, ROIC 37.7%, cap $1.10B) and AORT (Artivion Inc.) posts a D+ grade (54/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.14B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SGP?

Per SGP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001778922), SpyGlass Pharma Inc. generated $0 in revenue, -$39.9M in net income, and -$33.5M in free cash flow against $115.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SGP trading relative to its 50-day, 200-day, and 52-week technical levels?

SGP last traded at $32.51 (-1.06% on volume of 125,374 shares), positioning the stock +19.39% above its 50-day simple moving average ($27.23) and +33.46% above its 200-day simple moving average ($24.36). Across its 52-week range of $17.06 to $33.84, SGP sits at the 92.1% percentile with a 14-day RSI of 71.4 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($28.45 to $36.57).

SGP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is SpyGlass Pharma Inc. (SGP)?

In FY 2025 (10-K), SGP converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: SGP RQD Cockpit SGP 12M Forecast SGP Earnings & Move SGP Dividends & DRIP SGP Insiders & 13F SGP Whale Options SGP Profit Sankey SGP News & Why